NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.

Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...

Crypto prices are recovering after tensions between the U.S. and its NATO allies eased in what's become known as a taco ...

The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...

Roche's Gazyvaro, a drug that can restore kidney function in people living with lupus nephritis, has been cleared for use by ...

Bitcoin and ether were little changed alongside softer U.S. equity futures as investors leaned risk-off. Some altcoins bucked the trend due to thin liquidity.

Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...

Genmab plans to present full results at an upcoming medical meeting.

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

IBRX shares surge after updated data from the study of CD19 t-haNK show durable complete responses in Waldenstrom lymphoma ...

Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

Dye-based internalization detection reagents distinguish surface-bound from internalized ADCs to support drug optimization.